Thank you for your interest
Listen to the Podcast below or view a Transcript of the Podcast here
Checkpoint-binding Bispecific Antibodies: the Key to Go Beyond Combinations?
John Haurum, CEO, F-star Biotechnology Ltd.
Dr. John Haurum shares his perspective on the future of bispecific antibodies in the next 5 years, common myths about immune system activation using bispecifics and some novel compounds inside and outside of IO fields that he’s looking forward to the most at the Bispecific Antibody Pipeline Congress.
For more information, please visit www.BispecificAntibodyCongress.com/Bispecific-Antibody-Clinical-Relevance